Teva Stock Symbol Research and Valuation Analysis

Teva Pharmaceutical Industries Ltd. is traded under the stock symbol TEVA on the New York Stock Exchange (NYSE).

The company has a market capitalization of over $10 billion, making it one of the largest pharmaceutical companies in the world.

Teva's revenue has been steadily increasing over the years, reaching $24.2 billion in 2020.

This growth is largely due to the company's successful expansion into new markets and its strategic acquisitions.

Teva's diverse portfolio of medicines and vaccines covers a range of therapeutic areas, including respiratory, central nervous system, and oncology.

The company's strong research and development capabilities have enabled it to develop innovative treatments for various diseases.

Teva's valuation is influenced by its financial performance, market trends, and industry developments.

Curious to learn more? Check out: New Relic Stock Symbol

Teva's financial performance is a mixed bag. The company's profit margin is a concerning -0.94%, indicating that it's actually losing money on each dollar of sales.

The Return on Assets (ROA) is a relatively healthy 5.37%, suggesting that Teva is generating decent profits from its assets. However, the Return on Equity (ROE) is a negative -2.42%, which is a red flag.

Here's a quick snapshot of Teva's financials:

These numbers indicate that Teva is struggling to turn a profit, with a significant net loss and a negative earnings per share (EPS).

The company's stock price has been fluctuating, with a high of $20.05 and a low of $19.77. This indicates a range of $0.28.

The stock's open price was $20.00, while the previous close was $20.04. This suggests a slight decrease in value.

Here are the key statistics:

The company's market capitalization is $23.58 billion USD, which is a significant value.

In terms of financial strength, TEVA has a quick ratio of 0.48, which is lower than that of its peers, VTRS and SDZ, both of which have a quick ratio of 0.62 and 0.63 respectively.

The current ratio for TEVA is 1.06, which is lower than VTRS and SDZ, with current ratios of 1.37 and 1.29 respectively.

TEVA's interest coverage is 0.92, which is lower than SDZ's interest coverage of 2.04, but higher than VTRS's negative interest coverage of -6.53.

Here's a comparison of the quick ratio, current ratio, and interest coverage for TEVA and its peers:

Teva stock, as reflected in its financial reports, shows some concerning signs. Total Cash is a significant $2.16 billion, but the company's debt burden is substantial, with a Total Debt/Equity ratio of 256.69%.

The company's cash flow situation is also worth noting, with a Levered Free Cash Flow of $1.6 billion. This indicates that Teva has some financial flexibility, but it's essential to consider the bigger picture.

Here are some key financial metrics to keep in mind:

TEVA's financial situation is a bit concerning, with a total debt to equity ratio of 256.69%. This means the company has a significant amount of debt compared to its equity.

The company's total cash is 2.16 billion dollars, which is a decent amount but not enough to cover its debt.

Let's take a look at some key statistics. The average volume of TEVA's stock is 10.40 million shares, which is a decent trading volume.

Broaden your view: Is Preferred Stock Debt or Equity

Here's a breakdown of TEVA's profitability and income statement:

As you can see, TEVA's profit margin is negative, which indicates that the company is not generating enough revenue to cover its costs. The return on assets is relatively high, but the return on equity is negative, which suggests that the company is not generating enough profits for its shareholders. The revenue is substantial, but the net income is negative, which is a cause for concern.

Expand your knowledge: Why Is Treasury Stock Negative

Teva's olanzapine long-acting injectable has shown promising results in its SOLARIS phase 3 trial, with no reported cases of post-injection delirium/sedation syndrome events, or PDSS.

The company's schizophrenia treatment, Uzedy, has gained favor among healthcare professionals, who prefer it over Invega Sustenna.

Teva's stock has seen a 5% increase in value following the announcement of these positive results.

Take a look at this: Nflx Results

To compare Teva stock with similar companies, you can select up to 4 stocks for analysis using key performance metrics.

Teva has announced positive results for its olanzapine long-acting injectable in the SOLARIS phase 3 trial, with no reported post-injection delirium/sedation syndrome events.

The stock is up 5% on the news, which is a significant increase in value.

Healthcare professionals have also favored Teva's schizophrenia drug Uzedy over Invega Sustenna in a recent study.

Take a look at this: Teva Pharmaceuticals

When comparing stocks, it's essential to analyze similar companies using key performance metrics. This helps you make informed decisions about your investments.

You can select up to 4 stocks to compare with your target company. For example, comparing TEVA with other stocks can give you valuable insights.

Selecting similar companies allows you to evaluate their performance in different areas, such as revenue growth, profitability, and market capitalization. This helps you understand how your target company stacks up against its peers.

By comparing your target company with similar ones, you can identify potential strengths and weaknesses, and make more accurate predictions about its future performance.

Here's an interesting read: Servicenow Stock Price Target

Teva's olanzapine long-acting injectable showed promising results in the SOLARIS phase 3 data, with no reported post-injection delirium/sedation syndrome events.

Healthcare professionals have shown a preference for Teva's schizophrenia drug Uzedy over Invega Sustenna in a recent study.

The stock price of Teva has increased by 5% following the announcement of these positive results.

The data from the SOLARIS phase 3 study suggests that Teva's olanzapine long-acting injectable is a safe and effective treatment option.

This preference for Uzedy over Invega Sustenna could have significant implications for the treatment of schizophrenia.

For more insights, see: Preferred Stock Has Preference over Common Stock in the

Teva's valuation metrics are quite interesting. The market cap is a substantial 22.27B, while the enterprise value is 37.63B. The forward P/E ratio is a relatively low 7.06, indicating that investors expect the company to grow its earnings in the future.

The PEG ratio, which is a more comprehensive valuation metric, is unfortunately not provided. However, we can look at the price-to-sales ratio, which is 1.38. This is slightly higher than the industry average, suggesting that investors are willing to pay a premium for Teva's products.

Here's a summary of Teva's valuation metrics:

In terms of profitability, Teva's profit margin is a negative 0.94%, indicating that the company is currently losing money. However, the return on assets is a relatively healthy 5.37%, suggesting that the company is generating decent returns on its assets.

The valuation of a company is a crucial aspect to consider when analyzing its profitability.

Market capitalization for this company is a significant 22.27 billion dollars.

Enterprise value, on the other hand, is an even more substantial 37.63 billion dollars.

The forward price-to-earnings ratio is a relatively low 7.06.

We can also look at the price-to-sales ratio, which is 1.38.

Another metric is the price-to-book ratio, which is a high 3.37.

The enterprise value-to-revenue ratio is 2.26, while the enterprise value-to-EBITDA ratio is 19.81.

Here's a summary of the valuation metrics:

The price-to-earnings ratio is not available for this company.

Profitability is a crucial aspect of a company's financial health. A negative profit margin of -0.94% indicates that the company is currently losing money.

Return on Assets (ROA) is a key metric that measures a company's ability to generate profits from its assets. With an ROA of 5.37%, the company is managing to generate profits from its assets, but the normalized ROA of 7.43% for TEVA, 6.91% for VTRS, and 6.54% for SDZ shows that these companies are more efficient in generating profits from their assets.

The Return on Equity (ROE) is another important metric that measures a company's ability to generate profits from its shareholders' equity. Unfortunately, the company has a negative ROE of -2.42%, which means it's not generating profits for its shareholders.

However, the normalized ROE of 48.32% for TEVA, 16.15% for VTRS, and 15.70% for SDZ shows that these companies are generating significant profits for their shareholders.

Here's a summary of the normalized ROA and ROE for the companies:

Teva Pharmaceutical Industries has gained FDA approval for its injectable UZEDY to treat bipolar I disorder, expanding its market potential.

Analysts view the TEVA stock as undervalued, with a fair value estimate of $24.22.

This approval is a significant development for the company, but challenges like debt and reliance on key drugs remain.

The fair value estimate of $24.22 suggests that the stock has room for growth, despite its current market price.

You might enjoy: Represents the Shares Issued at Par Value

If you're looking to dive into the world of Teva stock, you'll first need to select the right symbol. This can be a bit overwhelming, but don't worry, we've got you covered.

There are over a dozen stock exchanges where Teva is listed, including the Tel Aviv Stock Exchange, NYSE, and SIX Swiss Exchange. You can find the full list below.

Once you've selected the right symbol, you can start comparing Teva to other companies. In fact, you can compare up to 4 stocks at a time using key performance metrics.

If you're interested in comparing Teva to other companies, you can select up to 4 stocks to analyze. This will give you a better understanding of how Teva stacks up against its competitors.

Here are some key performance metrics to consider when comparing Teva to other companies: